Skip to main content

Table 1 Demographic and serological findings from 522 subjects and 614 serum samples tested for MOG-IgG

From: MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin

Diagnostic categories Sample numbers Patient numbers Sex ratio (m:f) Age (ys), median MOG-IgG+, samples MOG-IgG+, patients MOG-IgG+, median§ AQP4-IgG +, MOG-IgG + patients
Group I 386 300 1:2.4 39 95/386 (24.6%) 50/300 (16.7%) 1:640 0/50 (0%)
 “ON and/or MY”a 281 202    95/281 (33.8%) 50/202 (24.8%) 1:640 0/50 (0%)
 “ON and MY”a 79 54    39/79 (49.4%) 22/54 (40.7%) 1:1280 0/22 (0%)
 “mON/rON”a 145 103    47/145 (32.4%) 22/103 (21.4%) 1:640 0/22 (0%)
 “mON”a 69 66    10/69 (14.5%) 9/66 (13.6%) 1:800 0/9 (0%)
 “rON”a 76 37    37/76 (48.7%) 13/37 (35.1%) 1:640 0/13 (0%)
 “MY” (all LETM)a 57 45    9/57 (15.8%) 6/45 (13.3%) 1:2560 0/6 (0%)
 “MS”a 58 54    0/58 (0%) 0/54 (0%) N.a. N.a.
 “OND”a 47 44    0/47 (0%) 0/44 (0%) N.a. N.a.
Group II 89 83 1:1.9 46 0/89 (0%) 0/83 (0%) N.a. 89/89 (100%)
 AQP4+ NMO 59 56    0/59 (0%) 0/56 (0%) N.a. 59/59 (100%)
 AQP4+ rON 5 5    0/25 (0%) 0/22 (0%) N.a. 25/25 (100%)
 AQP4+ LETM 25 22    0/5 (0%) 0/5 (0%) N.a. 5/5 (100%)
Group III 85 85 1:3 38 0/85 (0%) 0/85 (0%) N.a. N.a.
 RRMS 73 73    0/73 (0%) 0/73 (0%) N.a. N.a.
 SPMS 9 9    0/9 (0%) 0/9 (0%) N.a. N.a.
 PPMS 3 3    0/3 (0%) 0/3 (0%) N.a. N.a.
Group IV 54 54 1:1.3 38 1/54 (1.9%) 1/54 (1.9%) 1:320* 0/1 (0%)
 OND 9 9    1/9 (11.1%) 1/9 (11.1%) 1:320* 0/1 (0%)
 HC 45 45    0/45 (0%) 0/45 (0%) N.a. N.a.
Group II–IV 228 222 1:1.9 38 1/228 (0.5%) 1/222 (0.5%) 1:320* 0/1 (0%)
Total 614 522 1:2.6 38 96/614 (15.6%) 51/522 (9.8%) 1:640 0/51 (0%)
  1. N.a not applicable, ON optic neuritis, mON monophasic ON, rON recurrent ON, MY myelitis, LETM longitudinally extensive transverse myelitis, MS multiple sclerosis, OND other neurological disorders, RRMS relapsing remitting MS, SPMS secondary progressive MS, PPMS primary progressive MS, HC healthy control. aSuspected diagnosis at the time of sample referral. §MOG-IgG-positive samples only. *Single patient